Article: Sepracor Inc. and GlaxoSmithKline Announce International Alliance for Commercialization of LUNIVIA(R) (LUNESTA(R) in U.S.).

* Sepracor to Receive Licensing and Milestone Payments from GSK of up to $155 Million

* Marketing Authorization Application (MAA) for LUNIVIA brand eszopiclone is under European Medicines Agency (EMEA) review

* European Union (EU) Approval Targeted for Second Half of 2008

* European Insomnia Market Estimated at Approximately $500 Million in 2006

MARLBOROUGH, Mass. & LONDON -- Sepracor Inc. (Nasdaq: SEPR) and GlaxoSmithKline (GSK) today announced an agreement for the commercialization of Sepracor's eszopiclone product for all markets worldwide (excluding the U.S., Canada, Mexico and Japan). Sepracor's eszopiclone product will be ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!